Cancer drug tested to shrink hidden HIV and calm inflammation
NCT ID NCT05780073
Summary
This study tested if adding a low dose of the drug dasatinib to standard HIV medication is safe and can help control the virus. It involved 60 adults with well-controlled HIV who took dasatinib or a placebo pill daily for 24 weeks. Researchers wanted to see if dasatinib could reduce hidden virus reservoirs and lower harmful inflammation linked to long-term HIV infection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION PRIMARY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
Conditions
Explore the condition pages connected to this study.